Isis reports Phase II data for Factor XI inhibitor

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) said subcutaneous 300 mg ISIS-FXIRx led to a significant seven fold reduction in the rate of venous thromboembolism (VTE) vs. enoxaparin in a Phase II trial to prevent VTE in patients undergoing total knee replacement surgery (p<0.0001). The rate of VTE with a 200 mg dose of ISIS-FXIRx was similar to that with enoxaparin. Isis said patients receiving ISIS-FXIRx had numerically fewer bleeding events compared to patients receiving enoxaparin. The open-label, international trial enrolled 291 patients who received seven doses of 200 or 300 mg ISIS-FXIRx over six weeks prior to surgery and a dose at six hours and at three days after surgery, or enoxaparin the evening before surgery, 6-8 hours after surgery and daily for at least eight days after surgery. ...